


ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

(An Open Ended Equity Scheme following Pharma, Healthcare, Diagnostic and allied Theme.)

Category
Thematic

Style Box

Style



■ Diversified

Returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth Option as on August 31, 2023

Particulars	1 Year		3 Years		5 Years		Since inception	
	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000
Scheme	24.95	12502.63	17.02	16022.96	16.98	21911.36	18.32	23730.00
S&P BSE Healthcare TRI (Benchmark)	22.03	12209.27	15.67	15474.75	12.62	18120.17	15.13	20625.94
Nifty 50 TRI (Additional Benchmark)	9.50	10952.88	20.58	17531.73	11.83	17495.41	12.84	18599.91
NAV (Rs.) Per Unit (as on August 31,2023 : 23.73)	18.98		14.81		10.83		10.00	

Notes:

- Different plans shall have different expense structure. The performance details provided herein are of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund.
- The scheme is currently managed by Dharmesh Kakkad. Mr. Dharmesh Kakkad has been managing this fund since May 2020. Total Schemes managed by the Fund Manager(Equity) is 11 (9 are jointly managed). Refer annexure at the following [link](#) for performance of other funds being managed by the fund managers.
- Date of inception: 13-Jul-2018.
- Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment.
- Load is not considered for computation of returns.
- In case, the start/end date of the concerned period is a nonbusiness date (NBD), the NAV of the previous date is considered for computation of returns. The NAV per unit shown in the table is as on the start date of the said period.
- The performance of the scheme is benchmarked to the Total Return variant of the Index.

Scheme Details

Fund Managers** :

Dharmesh Kakkad
(Managing this fund since May, 2020 & Overall 13 years of experience)



Inception/Allotment date: 13-Jul-18



Monthly AAUM as on 31-Aug-23 : Rs. 3,134.80 crores

Closing AUM as on 31-Aug-23 : Rs. 3,174.41 crores



Application Amount for fresh Subscription :

Rs.5,000 (plus in multiple of Rs.1)



Indicative Investment Horizon: 5 years & above



Min.Addl.Investment :

Rs.1,000 (plus in multiples of Re.1)



Exit load for Redemption / Switch out

- Lumpsum & SIP / STP Option:

1% of the applicable NAV - If units purchased or switched in from another scheme of the Fund are redeemed or switched out within 15 days from the date of allotment NIL - If units purchased or switched in from another scheme of the Fund are redeemed or switched out after 15 days from the date of allotment (w.e.f. 1st Jan 2019)



Total Expense Ratio @@@ :

Other : 2.00% p. a.

Direct : 1.15% p. a.



No. of folios

in the Scheme :

1,14,991



NAV (As on 31-Aug-23): Growth Option : Rs. 23.73

IDCW Option : 16.4

Direct Plan Growth Option : Rs. 25.16

Direct Plan IDCW Option : 17.72



Portfolio as on August 31, 2023

Company/Issuer	% to NAV	% to NAV Derivatives	Company/Issuer	Rating	% to NAV	% to NAV Derivatives
Equity Shares	98.00%		Short Term Debt and net current assets		2.00%	
Healthcare Services	18.49%		Total Net Assets		100.00%	
• Apollo Hospitals Enterprise Ltd.	6.76%		• Top Ten Holdings			
• Aster DM Healthcare Ltd.	2.63%		Securities and the corresponding derivative exposure with less than 1% to NAV, have been clubbed together with a consolidated limit of 10%.			
• Krsnaa Diagnostics Ltd.	2.45%					
Fortis Healthcare Ltd.	2.44%					
Vijaya Diagnostic Centre Pvt Ltd.	1.69%					
Thyrocare Technologies Ltd.	1.30%					
Narayana Hrudayalaya Ltd.	1.23%					
Insurance	1.29%					
SBI Life Insurance Company Ltd.	1.29%					
Pharmaceuticals & Biotechnology	67.29%					
• Sun Pharmaceutical Industries Ltd.	15.17%					
• Dr. Reddy's Laboratories Ltd.	7.55%					
• Cipla Ltd.	7.51%					
• Lupin Ltd.	5.18%					
• Aurobindo Pharma Ltd.	4.06%					
• FDC Ltd.	3.76%					
• Alkem Laboratories Ltd.	3.57%					
• Glaxosmithkline Pharmaceuticals Ltd.	2.52%					
• IPCA Laboratories Ltd.	2.36%					
• Mankind Pharma Ltd	2.23%					
• Divi's Laboratories Ltd.	2.05%					
• Torrent Pharmaceuticals Ltd.	1.72%					
• Glenmark Pharmaceuticals Ltd.	1.71%					
• Piramam Pharma Ltd	1.61%					
• Indoco Remedies Ltd.	1.45%					
• Biocon Ltd.	1.37%					
• Dishman Carbogen Amcis Ltd.	1.36%					
• Eris Lifesciences Ltd.	1.11%					
• Windlas Biotech Ltd.	1.01%					
Foreign Equity	1.33%					
Pharmaceuticals	1.33%					
• Viatris Inc.	1.33%					
Equity less than 1% of corpus	9.59%					

Quantitative Indicators

Average Dividend Yield :

0.62

Annual Portfolio Turnover Ratio :

Equity - 0.66 times

Std Dev (Annualised) : 14.57%

Sharpe Ratio : 0.70

Portfolio Beta : 0.90

The figures are not netted for derivative transactions.

Risk-free rate based on the last Overnight MIBOR cut-off of 6.69%

@ Total Expense Ratio is as on the last day of the month.

**In addition to the fund manager managing this fund, overseas investment is managed by Ms. Shamila D'mello.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by ICICI Prudential Asset Management Company Ltd. Neither MSCI, S&P nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

To Refer to the annexure for details on option, entry load, SWP, STP/Flex STP & minimum redemption amount pertaining to the scheme. [Click here](#)

To Refer to the annexure for details on scheme objective, IDCW history and SIP details. [Click here](#)

Riskometer

This product labelling is applicable only to the scheme

This Product is suitable for investors who are seeking*:

- Long Term Wealth Creation
- An Equity Scheme that predominantly invest in pharma, healthcare, hospitals, diagnostics, wellness and allied companies.

Scheme



Investors understand that their principal will be at Very High risk

Benchmark

(S&P BSE Healthcare TRI)



Benchmark riskometer is at Very High risk.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

ICICI Prudential Mutual Fund Corporate Office

ONE BKC, A - Wing, 13th Floor, Bandra-Kurla Complex, Mumbai 400 051, India.

Tel: 022 - 26525000 Fax: 022 - 26528100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

Statutory Details & Risk Factors

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Disclaimer: In the preparation of the material contained in this document, the AMC has used information that is publicly available, including information developed in-house. Some of the material(s) used in the document may have been obtained from members/persons other than the AMC and/or its affiliates and which may have been made available to the AMC and/or to its affiliates. Information gathered and material used in this document is believed to be from reliable sources. The AMC however does not warrant the accuracy, reasonableness and / or completeness of any information. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions, that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc. ICICI Prudential Asset Management Company Limited (including its affiliates), the Mutual Fund, The Trust and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. Further, the information contained herein should not be construed as forecast or promise. The recipient alone shall be fully responsible/are liable for any decision taken on this material.